Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Clearside Biomedi (CLSD)

Clearside Biomedi (CLSD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,618
  • Shares Outstanding, K 60,191
  • Annual Sales, $ 29,580 K
  • Annual Income, $ 380 K
  • 60-Month Beta 1.84
  • Price/Sales 2.44
  • Price/Cash Flow N/A
  • Price/Book 3.89
Trade CLSD with:

Options Overview Details

View History
  • Implied Volatility 466.89% ( +118.11%)
  • Historical Volatility 77.80%
  • IV Percentile 95%
  • IV Rank 32.29%
  • IV High 1,382.86% on 09/07/22
  • IV Low 30.03% on 05/19/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 6,234
  • Open Int (30-Day) 6,168

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.14
  • Prior Year 0.31
  • Growth Rate Est. (year over year) -141.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0950 +2.28%
on 12/05/22
1.6100 -30.43%
on 11/14/22
-0.3700 (-24.83%)
since 11/04/22
3-Month
1.0000 +12.00%
on 09/30/22
1.6100 -30.43%
on 11/14/22
-0.2100 (-15.79%)
since 09/06/22
52-Week
1.0000 +12.00%
on 09/30/22
3.3800 -66.86%
on 12/09/21
-1.9100 (-63.04%)
since 12/06/21

Most Recent Stories

More News
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

CLSD : 1.1000 (-3.51%)
EVGN : 0.6200 (-1.59%)
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -151.06% and 92.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 27.65 (-3.49%)
CLSD : 1.1000 (-3.51%)
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

WVE : 4.21 (-0.94%)
CLSD : 1.1000 (-3.51%)
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0% and 48.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CLSD : 1.1000 (-3.51%)
RAPT : 16.01 (-3.15%)
Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

- CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty...

CLSD : 1.1000 (-3.51%)
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

- Transaction Supports Progression of CLS-AX Clinical Program -...

CLSD : 1.1000 (-3.51%)
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ANIP : 37.45 (-1.45%)
CLSD : 1.1000 (-3.51%)
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -122.58% and 2.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies...

BHVN : 15.88 (-2.70%)
CLSD : 1.1000 (-3.51%)
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of...

CLSD : 1.1000 (-3.51%)
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of...

CLSD : 1.1000 (-3.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious...

See More

Key Turning Points

3rd Resistance Point 1.3083
2nd Resistance Point 1.2567
1st Resistance Point 1.1983
Last Price 1.1000
1st Support Level 1.0883
2nd Support Level 1.0367
3rd Support Level 0.9783

See More

52-Week High 3.3800
Fibonacci 61.8% 2.4708
Fibonacci 50% 2.1900
Fibonacci 38.2% 1.9092
Last Price 1.1000
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar